Last Updated : May 1, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
| Brand Name | Generic Name | Therapeutic Area | Recommendation Type | Project Status | Date Submission Received Sort descending | Date Recommendation Issued |
|---|---|---|---|---|---|---|
| Evrysdi | risdiplam | Spinal muscular atrophy | Reimburse with clinical criteria and/or conditions | Complete | ||
| Unituxin | dinutuximab | Neuroblastoma | Reimburse with clinical criteria and/or conditions | Complete | ||
| Rybelsus | semaglutide | diabetes mellitus, type 2 | Reimburse with clinical criteria and/or conditions | Complete | ||
| Reblozyl | luspatercept | beta-thalassemia associated anemia | Reimburse with clinical criteria and/or conditions | Complete | ||
| Dupixent | dupilumab | Asthma | Reimburse with clinical criteria and/or conditions | Complete | ||
| Keytruda | pembrolizumab | Colorectal cancer | Reimburse with clinical criteria and/or conditions | Complete | ||
| Imfinzi | durvalumab | Extensive-stage small cell lung cancer | Reimburse with clinical criteria and/or conditions | Complete | ||
| Braftovi | encorafenib | Metastatic colorectal cancer | Reimburse with clinical criteria and/or conditions | Complete | ||
| Braftovi and Mektovi | encorafenib and binimetinib | Advanced Melanoma | Reimburse with clinical criteria and/or conditions | Complete | ||
| Abecma | idecabtagene vicleucel | Multiple myeloma | Do not reimburse | Complete |
Last Updated : May 1, 2024